2cureX announced that it will focus all resources on making IndiTreat®? testing available at hospitals worldwide by accelerating the development of an automated IVD system. To support the implementation of this strategy, the company has proposed Tonni Bulow-Nielsen as new Chairman of the Board, to be confirmed by the Extraordinary General Meeting on November 14th.

Expectations for 2023 have been revised, to adapt to the new strategic focus on automation. Leapfrogging to a new business model: 2cureX Board of Directors and Management Team have decided to focus its efforts in accelerating the development of an automated system - a combination of instrument, reagents, consumables, and software - that can be placed in a standard customer lab anywhere in the world and operated by their own staff to run the IndiTreat®? test.

By enabling in-house testing at customer's labs, 2cureX aims at leveraging its first mover advantage and building a global leader position in an emerging segment that is expected to become a multi-billion USD per year market. Full focus of the company's resources: The development of an automated system will require the company to fully focus on the activities that support this project. Specifically, this will mean: Concentrating all internal resources in the activities that support the development of an automated IndiTreat®?

system for multiple tumor entities - leveraging ongoing efforts in ovarian and pancreatic cancer - and preparing the launch of the system. Reducing by 30% all operating expenses not related to this project; Continue to run clinical studies to generate additional evidence and build trust in the IndiT treat®? technology among healthcare professionals; Leveraging unique customer reach to keep learning about the market, creating awareness, establishing relationships with oncologists, and identifying customers to become evaluators and early users of the automated system; Engaging hospitals in network to be first movers conducting IndiTreat®?

tested on-site; seeking additional funding both from investors and grants, to support the activities throughout the automated system development project.